Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
Anticancer Research|May 29, 2017
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant ChemotherapyTheofani Gavressea, Konstantine T Kalogeras, Georgia-Angeliki Koliou, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2008
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyGerasimos Aravantinos, George Fountzilas, Aristotelis Bamias, et al.
Anticancer Research|November 2, 2010
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancerHaralabos P Kalofonos, Pavlos Papakostas, Thomas Makatsoris, et al.
Anticancer Research|May 7, 2017
Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast CancerTitika-Marina Strati, Vassiliki Kotoula, Ioannis Kostopoulos, et al.
Clinical Breast Cancer|November 9, 2019
The Role of CXCL13 and CXCL9 in Early Breast CancerEvangelia Razis, Konstantine T Kalogeras, Ioannis Kotsantis, et al.
Breast Cancer Research and Treatment|December 22, 2011
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialHelen Gogas, Urania Dafni, Maria Karina, et al.
American Journal of Cancer Research|January 27, 2017
The fate of BRCA1-related germline mutations in triple-negative breast tumorsVassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, et al.
Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Medical Oncology (Northwood, London, England)|June 2, 2018
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotypingGeorge Papaxoinis, Vassiliki Kotoula, Eleni Giannoulatou, et al.
ESMO Open|June 25, 2019
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancerElena Fountzilas, Vassiliki Kotoula, George Pentheroudakis, et al.
Pageof 19